International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 70

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in *Cumulative List No. 14, 2011* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 70

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la *Liste récapitulative No. 14, 2011* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 70

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran reunidas en *Cumulative List No. 14, 2011* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

abiciparum pegolum #

abicipar pegol

pegylated composite protein for clinical applications (CPCA), with alternative scaffold domain to antigen receptors based on ankyrin repeats, anti-[*Homo sapiens* VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)];
glycyl-seryl-ankyrin repeats (3-35, 36-68, 69-101, 102-123)-lysyl-dialanyl-bis(triglycyl-seryl) linker (127-134)-cysteinyl (1-135), conjugated via a maleimide group linker (thioether bond to C135) to a single linear methoxy polyethylene glycol 20 (mPEG20)

abicipar pégol

protéine composite pour applications cliniques (CPCA) pégylée, avec une charpente de domaine alternative aux récepteurs d'antigènes basée sur des répétitions ankyrine, anti-[*Homo sapiens* VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)];
glycyl-séryl-domaine à répétitions ankyrine (3-35, 36-68, 69-101, 102-123)-lysyl-dialanyl-linker bis(triglycyl-séryl) (127-134)-cystéinyl (1-135), conjugué via un linker du groupe maléimide (liaison thioéther à C135) à une molécule linéaire unique de méthoxy polyéthylène glycol 20 (mPEG20)

abicipar pegol

proteína compuesta para aplicaciones clínicas (CPCA) pegilada, con una estructura de dominio alternativa a los receptores de antígenos basada en repeticiones de la ankirina, anti-[*Homo sapiens* VEGFA (factor A de crecimiento endotelial vascular, VEGF-A, VEGF)];
glicil-seril-dominio de repeticiones de ankirina (3-35, 36-68, 69-101, 102-123)-lisil-dialanil-conector bis(triglicil-seril) (127-134)-cisteinil (1-135), conjugado mediante un conector maleimida (enlace tioéter en C135) en una molécula lineal única de metoxi polietilenglicol 20 (mPEG20)

$C_{617}H_{969}N_{173}O_{199}S_2$ (protein component)

```
GSDLDKKLLE AARAGQDDEV RILMANGADV NARDSTGWTP LHLAAPWGHP  50
EIVEVLLKNG ADVNAADFQG WTPLHLAAAV GHLEIVEVLL KYGADVNAQD 100
KFGKTAFDIS IDNGNEDLAE ILQKAAGGGS GGGSC                135
```

afoxolanerum

afoxolaner

4-{5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl}-*N*-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}naphthalene-1-carboxamide

afoxolaner

4-{5-[3-chloro-5-(trifluorométhyl)phényl]-5-(trifluorométhyl)-4,5-dihydro-1,2-oxazol-3-yl}-*N*-{2-oxo-2-[(2,2,2-trifluoroéthyl)amino]éthyl}naphtalène-1-carboxamide

afoxolaner

4-{5-[3-cloro-5-(trifluorometil)fenil]-5-(trifluorometil)-4,5-dihidro-1,2-oxazol-3-il}-*N*-{2-oxo-2-[(2,2,2-trifluoroetil)amino]etil}naftaleno-1-carboxamida

$C_{26}H_{17}ClF_9N_3O_3$



and enantiomer
et énantiomère
y enantiómero

afuresertibum

afuresertib	*N*-[(2*S*)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)thiophene-2-carboxamide
afurésertib	*N*-[(2*S*)-1-amino-3-(3-fluorophényl)propan-2-yl]-5-chloro-4-(4-chloro-1-méthyl-1*H*-pyrazol-5-yl)thiophène-2-carboxamide
afuresertib	*N*-[(2*S*)-1-amino-3-(3-fluorofenil)propan-2-il]-5-cloro-4-(4-cloro-1-metil-1*H*-pirazol-5-il)tiofeno-2-carboxamida

$C_{18}H_{17}Cl_2FN_4OS$



albutrepenonacogum alfa #

albutrepenonacog alfa	human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component) 148-threonine variant fusion protein with prolyl(human coagulation factor IX 148-threonine variant-(137-153)-peptide) fusion protein with human serum albumin, produced in CHO cells (alfa glycoform)
albutrépénonacog alfa	variant 148-thréonine du facteur IX humain de la coagulation (EC 3.4.21.22, facteur Christmas, facteur antihémophilique B) protéine de fusion avec le prolyl(variant 148-thréonine du facteur IX humain de la coagulation-(137-153)-peptide), protéine de fusion avec l'albumine sérique humaine, produit par culture de cellules CHO (glycoforme alfa)
albutrepenonacog alfa	variante 148-treonina del factor IX humano de coagulación (EC 3.4.21.22, factor Christmas, factor antihemofílico B) proteína de fusión con prolil(variante 148-treonina del factor IX humano de la coagulación-(137-153)-péptido), proteína de fusión con albumina sérica humana, producida por cultivo de células CHO (glicoforma alfa)

$C_{5077}H_{7846}N_{1367}O_{1588}PS_{67}$ (peptide)

Sequence / Séquence / Secuencia

```
YNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTTE FWKQYVDGDQ 50
CESNPCLNGG SCKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK 100
NSADNKVVCS CTEGYRLAEN QKSCEPAVPF PCGRVSVSQT SKLTRAETVF 150
PDVDYVNSTE AETILDNITQ STQSFNDFTR VVGGEDAKPG QFPWQVVLNG 200
KVDAFCGGSI VNEKWIVTAA HCVETGVKIT VVAGEHNIEE TEHTEQKRNV 250
IRIIPHHNYN AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL 300
KFGSGYVSGW GRVFHKGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC 350
AGFHEGGRDS CQGDSGGPHV TEVEGTSFLT GIISWGEECA MKGKYGIYTK 400
VSRYVNWIKE KTKLTPVSQT SKLTRAETVF PDVDAHKSEV AHRFKDLGEE 450
NFKALVLIAF AQYLQQCPFE DHVKLVNEVT EFAKTCVADE SAENCDKSLH 500
TLFGDKLCTV ATLRETYGEM ADCCAKQEPE RNECFLQHKD DNPNLPRLVR 550
PEVDVMCTAF HDNEETFLKK YLYEIARRHP YFYAPELLFF AKRYKAAFTE 600
CCQAADKAAC LLPKLDELRD EGKASSAKQR LKCASLQKFG ERAFKAWAVA 650
RLSQRFPKAE FAEVSKLVTD LTKVHTECCH GDLLECADDR ADLAKYICEN 700
QDSISSKLKE CCEKPLLEKS HCIAEVENDE MPADLPSLAA DFVESKDVCK 750
NYAEAKDVFL GMFLYEYARR HPDYSVVLLL RLAKTYETTL EKCCAAADPH 800
ECYAKVFDEF KPLVEEPQNL IKQNCELFEQ LGEYKFQNAL LVRYTKKVPQ 850
VSTPTLVEVS RNLGKVGSKC CKHPEAKRMP CAEDYLSVVL NQLCVLHEKT 900
PVSDRVTKCC TESLVNRRPC FSALEVDETY VPKEFNAETF TFHADICTLS 950
EKERQIKKQT ALVELVKHKP KATKEQLKAV MDDFAAFVEK CCKADDKETC 1000
FAEEGKKLVA ASQAALGL                                    1018
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

18-23	51-62	56-71	73-82	88-99	95-109	111-124
132-289	206-222	336-350	361-389	486-495	508-524	523-534
557-602	601-610	633-679	678-686	698-712	711-722	749-794
793-802	825-871	870-881	894-910	909-920	947-992	991-1000

Modified residues / Résidus modifiés / Restos modificados



Glycosylation sites (**N,S,T**) / Sites de glycosylation (**N,S,T**) / Posiciones de glicosilación (**N,S,T**)
Ser-53* Ser-61* Asn-157 Thr-159* Asn-167 Thr-169* Thr-172* Thr-179*
* potential sites / sites potentiels / posiciones posibles

aldoxorubicinum

aldoxorubicin — *N*′-[(1*E*)-1-{(2*S*,4*S*)-4-[(3-amino-2,3,6-trideoxy-α-L-*lyxo*-hexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl}-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)hexanohydrazide

aldoxorubicine — *N*′-[(1*E*)-1-{(2*S*,4*S*)-4-[(3-amino-2,3,6-tridéoxy-α-L-*lyxo*-hexopyranosyl)oxy]-2,5,12-trihydroxy-7-méthoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotétracén-2-yl}-2-hydroxyéthylidène]-6-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)hexanohydrazide

aldoxorubicina — *N*′-[(1*E*)-1-{(2*S*,4*S*)-4-[(3-amino-2,3,6-tridesoxi-α-L-*lyxo*-hexopiranosil)oxi]-2,5,12-trihidroxi-7-metoxi-6,11-dioxo-1,2,3,4,6,11-hexahidrotetracen-2-il}-2-hidroxietilideno]-6-(2,5-dioxo-2,5-dihidro-1*H*-pirrol-1-il)hexanohidrazida

$C_{37}H_{42}N_4O_{13}$



alectinibum

alectinib — 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5*H*-benzo[*b*]carbazole-3-carbonitrile

alectinib — 9-éthyl-6,6-diméthyl-8-[4-(morpholin-4-yl)pipéridin-1-yl]-11-oxo-6,11-dihydro-5*H*-benzo[*b*]carbazole-3-carbonitrile

alectinib — 9-etil-6,6-dimetil-8-[4-(morfolin-4-il)piperidin-1-il]-11-oxo-6,11-dihidro-5*H*-benzo[*b*]carbazol-3-carbonitrilo

$C_{30}H_{34}N_4O_2$



apitolisibum

apitolisib — (2*S*)-1-(4-{[2-(2-aminopyrimidin-5-yl)-7-methyl-4-(morpholin-4-yl)thieno[3,2-*d*]pyrimidin-6-yl]methyl}piperazin-1-yl)-2-hydroxypropan-1-one

apitolisib — (2*S*)-1-(4-{[2-(2-aminopyrimidin-5-yl)-7-méthyl-4-(morpholin-4-yl)thiéno[3,2-*d*]pyrimidin-6-yl]méthyl}pipérazin-1-yl)-2-hydroxypropan-1-one

apitolisib — (2*S*)-1-(4-{[2-(2-aminopirimidin-5-il)-7-metil-4-(morfolin-4-il)tieno[3,2-*d*]pirimidin-6-il]metil}piperazin-1-il)-2-hidroxipropan-1-ona

$C_{23}H_{30}N_8O_3S$



belnacasanum

belnacasan — 1-[(2*S*)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl]-*N*-[(2*R*,3*S*)-2-ethoxy-5-oxooxolan-3-yl]-L-prolinamide

belnacasan — 1-[(2*S*)-2-(4-amino-3-chlorobenzamido)-3,3-diméthylbutanoyl]-*N*-[(2*R*,3*S*)-2-éthoxy-5-oxooxolan-3-yl]-L-prolinamide

belcanasán — 1-[(2*S*)-2-(4-amino-3-clorobenzamido)-3,3-dimetilbutanoil]-*N*-[(2*R*,3*S*)-2-etoxi-5-oxooxolan-3-il]-L-prolinamida

$C_{24}H_{33}ClN_4O_6$



bimagrumabum #

bimagrumab — immunoglobulin G1-lambda2, anti-[*Homo sapiens* ACVR2B (activin A receptor type IIB, ActR-IIB, ActRIIB) and ACVR2A (activin A receptor type IIA, ActR-II, ActRIIA)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-445) [*Homo sapiens* VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-213), hinge (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (224-224'':227-227'')-bisdisulfide

bimagrumab — immunoglobuline G1-lambda2, anti-[*Homo sapiens* ACVR2B (récepteur type IIB de l'activine A, ActR-IIB, ActRIIB) et ACVR2A (recepteur type IIA de l'activine A, ActR-II, ActRIIA)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-445) [*Homo sapiens* VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-213), charnière (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (224-224'':227-227'')-bisdisulfure

bimagrumab — inmunoglobulina G1-lambda2, anti-[*Homo sapiens* ACVR2B (receptor tipo IIB de la activina A, ActR-IIB, ActRIIB) y ACVR2A (receptor tipo IIA de la activina A, ActR-II, ActRIIA)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-445) [*Homo sapiens* VH (IGHV1-2*02 (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-213), bisagra (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (224-224'':227-227'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SSYINWVRQA PGQGLEWMGT  50
INPVSGSTSY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARGG 100
WFDYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KRVEPKSCDK THTCPPCPAP EAAGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
QSALTQPASV SGSPGQSITI SCTGTSSDVG SYNYVNWYQQ HPGKAPKLMI  50
YGVSKRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC GTFAGGSYYG 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 142-198 259-319 365-423
22"-96" 142"-198" 259"-319" 365"-423"
Intra-L 22'-90' 139'-198'
22'"-90'" 139'"-198'"
Inter-H-L 218-216' 218"-216'"
Inter-H-H 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"

brilacidinum

brilacidin

N^4,N^6-bis[3-{[5-(carbamimidamido)pentanoyl]amino}-2-{[(3*R*)-pyrrolidin-3-yl]oxy}-5-(trifluoromethyl)phenyl]pyrimidine-4,6-dicarboxamide

brilacidine

N^4,N^6-bis[3-{[5-(carbamimidamido)pentanoyl]amino}-2-{[(3*R*)-pyrrolidin-3-yl]oxy}-5-(trifluorométhyl)phényl]pyrimidine-4,6-dicarboxamide

brilacidina

N^4,N^6-bis[3-{[5-(carbamimidamido)pentanoil]amino}-2-{[(3*R*)-pirrolidin-3-il]oxi}-5-(trifluorometil)fenil]pirimidina-4,6-dicarboxamida

$C_{40}H_{50}F_6N_{14}O_6$



concizumabum #

concizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* TFPI (tissue factor pathway inhibitor, lipoprotein-associated coagulation inhibitor)], humanized monoclonal antibody;
gamma4 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV3-21*01 (85.70%) -(IGHD)-IGHJ3*01 M11>T (116)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01 (CH1 (122-219), hinge S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-29*02 (90.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimer (227-227":230-230")-bisdisulfide

concizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* TFPI (inhibiteur de la voie du facteur tissulaire, inhibiteur de la coagulation associé aux lipoprotéines)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-448) [VH humanisé (*Homo sapiens* IGHV3-21*01 (85.70%) -(IGHD)- IGHJ3*01 M11>T (116)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01 (CH1 (122-219), charnière S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-29*02 (90.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (227-227":230-230")-bisdisulfure

concizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* TFPI (inhibidor de la vía del factor tisular, inhibidor de la coagulación asociado a lipoproteínas)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-448) [VH humanizado (*Homo sapiens* IGHV3-21*01 (85.70%) -(IGHD)- IGHJ3*01 M11>T (116)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01 (CH1 (122-219), bisagra S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-29*02 (90.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVKPGGSLRL SCAASGFTFS NYAMSWVRQT PEKRLEWVAT  50
ISRSGSYSYF PDSVQGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARLG 100
GYDEGDAMDS WGQGTTVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCKSSQSLL ESDGKTYLNW YLQKPGQSPQ  50
LLIYLVSILD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQATHFP 100
QTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 148-204 262-322 368-426
22"-96" 148"-204" 262"-322" 368"-426"
Intra-L 23'-93' 139'-199'
23'"-93'" 139'"-199'"
Inter-H-L 135-219' 135"-219'"
Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"

copanlisibum

copanlisib — 2-amino-*N*-{7-methoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-*c*]quinazolin-5-yl}pyrimidine-5-carboxamide

copanlisib — 2-amino-*N*-{7-méthoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-*c*]quinazolin-5-yl}pyrimidine-5-carboxamide

copanlisib — 2-amino-*N*-{7-metoxi-8-[3-(morfolin-4-il)propoxi]-2,3-dihidroimidazo[1,2-*c*]quinazolin-5-il}pirimidina-5-carboxamida

$C_{23}H_{28}N_8O_4$



deferitazolum

deferitazole — (4*S*)-2-(2-hydroxy-3-{[(methoxyethoxy)ethoxy]ethoxy}phenyl)-4-methyl-4,5-dihydro-1,3-thiazol-4-carboxylic acid

déféritazole — acide (4*S*)-2-{2-hydroxy-3-{[(méthoxyéthoxy)éthoxy]éthoxy}phenyl)-4-méthyl-4,5-dihydro-1,3-thiazole-4-carboxylique

deferitazol — ácido (4*S*)-2-(2-hidroxi-4-metil -3-{[(metoxietoxi)etoxi]etoxi}fenil)-4,5-dihidro-1,3-tiazol-4-carboxílico

$C_{18}H_{25}NO_7S$



deleobuvirum

deleobuvir — (2*E*)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1*H*-indole-6-carboxamido]cyclobutyl}-1-methyl-1*H*-benzimidazol-6-yl)prop-2-enoic acid

déléobuvir — acide (2*E*)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-méthyl-1*H*-indole-6-carboxamido]cyclobutyl}-1-méthyl-1*H*-benzimidazol-6-yl)prop-2-énoïque

deleobuvir — ácido (2*E*)-3-(2-{1-[2-(5-bromopirimidin-2-il)-3-ciclopentil-1-metil-1*H*-indol-6-carboxamido]ciclobutil}-1-metil-1*H*-benzimidazol-6-il)prop-2-enoico

$C_{34}H_{33}BrN_6O_3$



delparantagum

delparantag — N^2-{5-[(5-{5-{L-lysylamino}-2-methoxybenzoyl-L-lysylamino}-2-methoxybenzoyl-L-lysyl)amino]-2-methoxybenzoyl}-*N*-(3-carbamoyl-4-methoxyphenyl)-L-lysinamide

delparantag — N^2-{5-[(5-{5-{L-lysylamino}-2-méthoxybenzoyl-L-lysylamino}-2-méthoxybenzoyl-L-lysyl)amino]-2-méthoxybenzoyl}-*N*-(3-carbamoyl-4-méthoxyphényl)-L-lysinamide

delparantag — N^2-{5-[(5-{5-{L-lisilamino}-2-metoxibenzoil-L-lisilamino}-2-metoxibenzoil-L-lisil)amino]-2-metoxibenzoil}-*N*-(3-carbamoil-4-metoxfenil)-L-lisinamida

$C_{56}H_{79}N_{13}O_{12}$



dupilumabum #

dupilumab — immunoglobulin G4-kappa, anti-[*Homo sapiens* IL4R (interleukin 4 receptor, IL4RA, IL-4RA, CD124)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*04 (92.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K130>del (451)) (126-451)], (139-219')-disulfide with kappa light chain (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-28*01 (96.00%) -IGKJ2*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dimer (231-231'':234-234'')-bisdisulfide

dupilumab — immunoglobuline G4-kappa, anti-[*Homo sapiens* IL4R (récepteur de l'interleukine 4, IL4RA, IL-4RA, CD124)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-451) [*Homo sapiens* VH (IGHV3-23*04 (92.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223), charnière S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K130>del (451)) (126-451)], (139-219')-disulfure avec la chaîne légère kappa (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-28*01 (96.00%) -IGKJ2*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dimère (231-231'':234-234'')-bisdisulfure

dupilumab — inmunoglobulina G4-kappa, anti-[*Homo sapiens* IL4R (receptor de la interleukina 4, IL4RA, IL-4RA, CD124)], anticuerpo monoclonal de *Homo sapiens;*
cadena pesada gamma4 (1-451) [*Homo sapiens* VH (IGHV3-23*04 (92.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-223),bisagra S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K130>del (451)) (126-451)], (139-219')-disulfuro con la cadena ligera kappa (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-28*01 (96.00%) -IGKJ2*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dímero (231-231'':234-234'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LEQPGGSLRL SCAGSGFTFR DYAMTWVRQA PGKGLEWVSS  50
ISGSGGNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDR 100
LSITIRPRYY GLDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350
PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450
G                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPLS LPVTPGEPAS ISCRSSQSLL YSIGYNYLDW YLQKSGQSPQ  50
LLIYLGSNRA SGVPDRFSGS GSGTDFTLKI SRVEAEDVGF YYCMQALQTP 100
YTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                    219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96     152-208     266-326     372-430
          22"-96"   152"-208"   266"-326"   372"-430"
Intra-L   23'-93'    139'-199'
          23'"-93'"   139'"-199'"
Inter-H-L   139-219'   139"-219'"
Inter-H-H   231-231"   234-234"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
302, 302"

dusigitumabum #

dusigitumab	immunoglobulin G2-lambda2, anti-[*Homo sapiens* IGF1 (insulin-like growth factor 1, somatomedin C) and IGF2 (insulin-like growth factor 2, somatomedin A)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-446) [*Homo sapiens* VH (IGHV1-8*01 (100.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-218), hinge (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (95.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimer (222-222":223-223":226-226":229-229")-tetrakisdisulfide
dusigitumab	immunoglobuline G2-lambda2, anti-[*Homo sapiens* IGF1 (facteur de croissance 1 analogue à l'insuline, somatomédine C) et IGF2 (facteur de croissance 2 analogue à l'insuline, somatomédine A)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-446) [*Homo sapiens* VH (IGHV1-8*01 (100.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-218), charnière (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (95.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimère (222-222":223-223":226-226":229-229")-tétrakisdisulfure
dusigitumab	inmunoglobulina G2-lambda2, anti-[*Homo sapiens* IGF1 (factor de crecimiento análogo a la insulina tipo 1, somatomedina C) y IGF2 (factor de crecimiento análogo a la insulina tipo 2, somatomedina A)], anticuerpo monoclonal de *Homo sapiens* ; cadena pesada gamma2 (1-446) [*Homo sapiens* VH (IGHV1-8*01 (100.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-218), bisagra (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (95.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dímero (222-222":223-223":226-226":229-229")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYDINWVRQA TGQGLEWMGW  50
MNPNSGNTGY AQKFQGRVTM TRNTSISTAY MELSSLRSED TAVYYCARDP 100
YYYYYGMDVW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT 200
YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTFR 300
VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP IEKTISKTKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPMLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSV SAAPGQKVTI SCSGSSSNIE NNHVSWYQQL PGTAPKLLIY  50
DNNKRPSGIP DRFSGSKSGT SATLGITGLQ TGDEADYYCE TWDTSLSAGR 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 147-203 260-320 366-424
22"-96" 147"-203" 260"-320" 366"-424"
Intra-L 22'-89' 139'-198'
22'"-89'" 139'"-198'"
Inter-H-L 134-216' 134"-216'"
Inter-H-H 222-222" 223-223" 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H VH N81:
73, 73"
H CH2 N84.4:
296, 296"

elosulfasum alfa #

elosulfase alfa

human *N*-acetylgalactosamine-6-sulfatase (chondroitinsulfatase, galactose-6-sulfate sulfatase, EC=3.1.6.4) dimer (139-139')-disulfide glycosylated (produced by CHO cells)

élosulfase alfa

N-acétylgalactosamine-6-sulfatase humaine (chondroïtinesulfatase, 6-sulfate de galactose sulfatase, EC=3.1.6.4) (139-139')-disulfure du dimère glycosylée (produite par des cellules CHO)

elosulfasa alfa

N-acetilgalactosamina-6-sulfatasa humana (condroitinsulfatasa, 6-sulfato de galactosa sulfatasa, EC=3.1.6.4) (139-139')-disulfuro del dímero glicosilado (producido por células CHO)

$C_{5020}H_{7574}N_{1364}O_{1418}S_{34}$

Monomer / Monomère / Monómero

```
APQPPNILLL LMDDMGWGDL GVYGEPSRET PNLDRMAAEG LLFPNFYSAN 50
PLCSPSRAAL LTGRLPIRNG FYTTNAHARN AYTPQEIVGG IPDSEQLLPE 100
LLKKAGYVSK IVGKWHLGHR PQFHPLKHGF DEWFGSPNCH FGPYDNKARP 150
NIPVYRDWEM VGRYYEEFPI NLKTGEANLT QIYLQEALDF IKRQARHHPF 200
FLYWAVDATH APVYASKPFL GTSQRGRYGD AVREIDDSIG KILELLQDLH 250
VADNTFVFFT SDNGAALISA PEQGGSNGPF LCGKQTTFEG GMREPALAWW 300
PGHVTAGQVS HQLGSIMDLF TTSLALAGLT PPSDRAIDGL NLLPTLLQGR 350
LMDRPIFYYR GDTLMAATLG QHKAHFWTWT NSWENFRQGI DFCPGQNVSG 400
VTTHNLEDHT KLPLIFHLGR DPGERFPLSF ASAEYQEALS RITSVVQQHQ 450
EALVPAQPQL NVCNWAVMNW APPGCEKLGK CLTPPESIPK KCLWSH     496
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
139-139' 282-393 282'-393' 463-492 463'-492' 475-481 475'-481'

Modified residues / Résidus modifiés / Restos modificados



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-178 Asn-178' Asn-397 Asn-397'

emapticapum pegolum

emapticap pegol

β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanosine 6-{2-(*N*-[ω-methylpoly(oxyethan-1,2-diyl)]-2-{[ω-methylpoly(oxyethan-1,2-diyl)]oxy}acetamido)acetamido}hexyl hydrogen 5'-phosphate

émapticap pégol

β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanosine 5'-hydrogénophosphate de 6-{2-(*N*-[ω-méthylpoly(oxyéthan-1,2-diyl)]-2-{[ω-méthylpoly(oxyéthan-1,2-diyl)]oxy}acétamido)acétamido}hexyle

emapticap pegol

β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanosina 5'-hydrógenofosfato de 6-{2-(*N*-[ω-metilpoli(oxietan-1,2-diil)]-2-{[ω-metilpoli(oxietan-1,2-diil)]oxi}acetamido)acetamido}hexilo

$C_{393}H_{501}N_{153}O_{286}P_{40}[C_2H_4O]_{2n}$

β-L-ribo-[(3'-5')-R-pG-C-A-C-G-U-C-C-C-U-C-A-C-C-G-G-U-G-C-A-A-G-U-G-A-A-G-C-C-G-U-G-G-C-U-C-U-G-C-G]

R- =



emixustatum

emixustat (1*R*)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol

émixustat (1*R*)-3-amino-1-[3-(cyclohexylméthoxy)phényl]propan-1-ol

emixustat (1*R*)-3-amino-1-[3-(ciclohexilmetoxi)fenil]propan-1-ol

$C_{16}H_{25}NO_2$



entolimodum #

entolimod L-methionyl-L-arginylglycyl-L-seryl-hexa(L-histidyl)glycyl-(*Enterobacteria phage T7* major capsid protein 10A-(1-11)-peptidyl)-L-arginyl-L-aspartyl-L-leucyl-L-tyrosyl-tetra(L-aspartyl)-L-lysyl-L-aspartyl-L-prolyl-(*Salmonella dublin* flagellin-(1-176)-peptidyl)-L-seryl-L-prolylglycyl-L-isoleucyl-L-seryl-pentaglycyl-L-isoleucyl-L-leucyl-L-aspartyl-L-seryl-L-methionylglycyl-(*Salmonella dublin* flagellin-(402-505)-peptide)

entolimod L-méthionyl-L-arginylglycyl-L-séryl-hexa(L-histidyl)glycyl-(principale protéine (10A) de la capside de l'*Enterobacteria phage T7* -(1-11)-peptidyl)-L-arginyl-L-aspartyl-L-leucyl-L-tyrosyl-tétra(L-aspartyl)-L-lysyl-L-aspartyl-L-prolyl-(flagelline de *Salmonella dublin* -(1-176)-peptidyl)-L-séryl-L-prolylglycyl-L-isoleucyl-L-séryl-pentaglycyl-L-isoleucyl-L-leucyl-L-aspartyl-L-séryl-L-méthionylglycyl-(flagelline de *Salmonella dublin*-(402-505)-peptide)

entolimod L-metionil-L-arginilglicil-L-seril-hexa(L-histidil)glicil-(proteína principal (10A) de la cápsida del *Enterobacteria fago T7* -(1-11)-peptidil)-L-arginil-L-aspartil-L-leucil-L-tirosil-tetra(L-aspartil)-L-lisil-L-aspartil-L-prolil-(flagelina de *Salmonella dublin* -(1-176)-peptidil)-L-seril-L-prolilglicil-L-isoleucil-L-seril-pentaglicil-L-isoleucil-L-leucil-L-aspartil-L-seril-L-metionilglicil-(flagelina de *Salmonella dublin*-(402-505)-péptido)

$C_{1464}H_{2419}N_{457}O_{519}S_8$

```
MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDPMAQVINT NSLSLLTQNN 50
LNKSQSSLSS AIERLSSGLR INSAKDDAAG QAIANRFTSN IKGLTQASRN 100
ANDGISIAQT TEGALNEINN NLQRVRELSV QATNGTNSDS DLKSIQDEIQ 150
QRLEEIDRVS NQTQFNGVKV LSQDNQMKIQ VGANDGETIT IDLQKIDVKS 200
LGLDGFNVNS PGISGGGGGI LDSMGTLINE DAAAAKKSTA NPLASIDSAL 250
SKVDAVRSSL GAIQNRFDSA ITNLGNTVTN LNSARSRIED ADYATEVSNM 300
SKAQILQQAG TSVLAQANQV PQNVLSLLR                        329
```

eravacyclinum

eravacycline (4*S*,4a*S*,5a*R*,12a*S*)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

éravacycline (4*S*,4a*S*,5a*R*,12a*S*)-4-(diméthylamino)-7-fluoro-3,10,12,12a-tétrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acétamido]-1,4,4a,5,5a,6,11,12a-octahydrotétracème-2-carboxamide

eravaciclina (4*S*,4a*S*,5a*R*,12a*S*)-4-(dimetilamino)-7-fluoro-3,10,12,12a-tetrahidroxi-1,11-dioxo-9-[2-(pirrolidin-1-il)acetamido]-1,4,4a,5,5a,6,11,12a-octahidrotetraceno-2-carboxamida

$C_{27}H_{31}FN_4O_8$



evodenosonum

evodenoson — methyl 4-{3-[6-amino-9-(*N*-cyclopropyl-β-D-ribofuranosyluronamide)-9*H*-purin-2-yl]prop-2-yn-1-yl}piperidine-1-carboxylate

évodénoson — 4-{3-[6-amino-9-(*N*-cyclopropyl-β-D-ribofuranosyluronamide)-9*H*-purin-2-yl]prop-2-yn-1-yl}pipéridine-1-carboxylate de méthyle

evodenosón — 4-{3-[6-amino-9-(*N*-ciclopropil-β-D-ribofuranosiluronamida)-9*H*-purin-2-il]prop-2-in-1-il}piperidina-1-carboxilato de metilo

$C_{23}H_{29}N_7O_6$



evolocumabum #

evolocumab — immunoglobulin G2-lambda, anti-[*Homo sapiens* PCSK9 (proprotein convertase subtilisin/kexin type 9)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain (1-441) [*Homo sapiens* VH (IGHV1-18*01 (93.90%) -(IGHD)-IGHJ6*01)) [8.8.8] (1-115) -IGHG2*01 (CH1 (116-213), hinge (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-214')-disulfide with lambda light chain (1'-215') [*Homo sapiens* V-LAMBDA (IGLV2-14*01 (95.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimer (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfide

évolocumab — immunoglobuline G2-lambda, anti-[*Homo sapiens* PCSK9 (proprotéine convertase subtilisine/kexine type 9)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma2 (1-441) [*Homo sapiens* VH (IGHV1-18*01 (93.90%) -(IGHD)-IGHJ6*01) [8.8.8] (1-115) - IGHG2*01 (CH1 (116-213), charnière (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-214')-disulfure avec la chaîne légère lambda (1'-215') [*Homo sapiens* V-LAMBDA (IGLV2-14*01 (95.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimère (217-217'':218-218'':221-221'':224-224'')-tétrakisdisulfure

evolocumab

inmunoglobulina G2-lambda, anti-[*Homo sapiens* PCSK9 (proproteína convertasa subtilisina/kexina tipo 9)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma2 (1-441) [*Homo sapiens* VH (IGHV1-18*01 (93.90%) -(IGHD)-IGHJ6*01) [8.8.8] (1-115) - IGHG2*01 (CH1 (116-213), bisagra(214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-214')-disulfuro con la cadena ligera lambda (1'-215') [*Homo sapiens* V-LAMBDA (IGLV2-14*01 (95.90%) - IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dímero (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGASVKV SCKASGYTLT SYGISWVRQA PGQGLEWMGW  50
VSFYNGNTNY AQKLQGRGTM TTDPSTSTAY MELRSLRSDD TAVYYCARGY 100
GMDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSN FGTQTYTCNV 200
DHKPSNTKVD KTVERKCCVE CPPCPAPPVA GPSVFLFPPK PKDTLMISRT 250
PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL 300
TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLPPSRE 350
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL 400
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K          441
```

Light chain / Chaîne légère / Cadena ligera

```
ESALTQPASV SGSPGQSITI SCTGTSSDVG GYNSVSWYQQ HPGKAPKLMI  50
YEVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC NSYTSTSMVF 100
GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
EGSTVEKTVA PTECS                                      215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96   142-198    255-315    361-419
          22"-96"  142"-198"  255"-315"  361"-419"
Intra-L   22'-90'    137'-196'
          22'''-90'''  137'''-196'''
Inter-H-L  129-214'  129"-214'''
Inter-H-H  217-217"  218-218"  221-221"  224-224"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

```
H CH2 N84.4:
291, 291"
```

fedratinibum

fedratinib

N-tert-butyl-3-[(5-methyl-2-{4-[2-(pyrrolidin-1-yl)ethoxy]anilino}pyrimidin-4-yl)amino]benzenesulfonamide

fédratinib

N-tert-butyl-3-[(5-méthyl-2-{4-[2-(pyrrolidin-1-yl)éthoxy]anilino}pyrimidin-4-yl)amino]benzènesulfonamide

fedratinib

N-terc-butil-3-[(5-metil-2-{4-[2-(pirrolidin-1-il)etoxi]anilino}pirimidin-4-il)amino]bencenosulfonamida

$C_{27}H_{36}N_6O_3S$



filgotinibum

filgotinib — *N*-(5-{4-[(1,1-oxo-λ^6-thiomorpholin-4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-*a*]pyridin-2-yl)cyclopropanecarboxamide

filgotinib — *N*-(5-{4-[(1,1-oxo-λ^6-thiomorpholin-4-yl)méthyl]phényl}[1,2,4]triazolo[1,5-*a*]pyridin-2-yl)cyclopropanecarboxamide

filgotinib — *N*-(5-{4-[(1,1-oxo-λ^6-tiomorfolin-4-il)metil]fenil}[1,2,4]triazolo[1,5-*a*]piridin-2-il)ciclopropanocarboxamida

$C_{21}H_{23}N_5O_3S$



filorexantum

filorexant — [(2*R*,5*R*)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone

filorexant — [(2*R*,5*R*)-5-{[(5-fluoropyridin-2-yl)oxy]méthyl}-2-méthylpipéridin-1-yl][5-méthyl-2-(pyrimidin-2-yl)phényl]méthanone

filorexant — [(2*R*,5*R*)-5-{[(5-fluoropiridin-2-il)oxi]metil}-2-metilpiperidin-1-il][5-metil-2-(pirimidin-2-il)fenil]metanona

$C_{24}H_{25}FN_4O_2$



finerenonum

finerenone — (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide

finérénone — (4S)-4-(4-cyano-2-méthoxyphényl)-5-éthoxy-2,8-diméthyl-1,4-dihydro-1,6-naphtyridine-3-carboxamide

finerenona — (4*S*)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida

$C_{21}H_{22}N_4O_3$



firtecanum peglumerum

firtecan peglumer

α-{3-[(α-*N*-acetylpoly-L-glutamyl)amino]propyl}-ω-methoxypoly(oxyethan-1,2-diyl) where the free γ-carboxyl groups are partially esterified by (4*S*)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl, partially converted to an amide with (propan-2-yl)[(propan-2-yl)carbamoyl]amino and partially unchanged

firtécan péglumère

α-{3-[(α-*N*-acétylpoly-L-glutamyl)amino]propyl}-ω-méthoxypoly(oxyéthylène) dont certains acides γ-carboxyliques sont estérifiés par le (4*S*)-4,11-diéthyl-4-hydroxy-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-9-yle et d'autres amidifiés par le (propan-2-yl)[(1-propan-2-yl)carbamoyl]amino

firtecán peglúmero

α-{3-[(α-*N*-acetilpoli-L-glutamil)amino]propil}-ω-metoxipoli(oxietileno) cuyos algunos ácidos γ-carboxílicos estan esterificados por el (4*S*)-4,11-dietil-4-hidroxi-3,14-dioxo-3,4,12,14-tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolein-9-ilo y otros amidificados por el (propan-2-il)[(propan-2-il)carbamoil]amino

$C_6H_{13}NO_2$ $[C_5H_6NO_2]_a$ $[C_2H_4O]_n$ $(C_{22}H_{19}N_2O_5)_x$ $(C_7H_{15}N_2O)_y$ $(HO)_z$

$a = x + y + z$



flortanidazolum (^{18}F)

flortanidazole (^{18}F)

(2*RS*)-3-[^{18}F]fluoro-2-{4-[(2-nitro-1*H*-imidazol-1-yl)methyl]-1*H*-1,2,3-triazol-1-yl}propan-1-ol

flortanidazole (^{18}F)

(2*RS*)-3-[^{18}F]fluoro-2-{4-[(2-nitro-1*H*-imidazol-1-yl)méthyl]-1*H*-1,2,3-triazol-1-yl}propan-1-ol

flortanidazol (^{18}F)

(2*RS*)-3-[^{18}F]fluoro-2-{4-[(2-nitro-1*H*-imidazol-1-il)metil]-1*H*-1,2,3-triazol-1-il}propan-1-ol

$C_9H_{11}{}^{18}FN_6O_3$



and enantiomer
et énantiomère
y enantiómero

flotegatidum (^{18}F)

flotegatide (^{18}F) — cyclo{L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-*N*^{6}-[2,6-anhydro-7-deoxy-7-({2-[4-(3-[^{18}F]fluoropropyl)-1*H*-1,2,3-triazol-1-yl]acetyl}amino)-L-*glycero*-L-*galacto*-heptonoyl]-L-lysyl}

flotégatide (^{18}F) — cyclo{L-arginylglycyl-L-α-aspartyl-D-phénylalanyl-*N*^{6}-[2,6-anhydro-7-déoxy-7-({2-[4-(3-[^{18}F]fluoropropyl)-1*H*-1,2,3-triazol-1-yl]acétyl}amino)-L-*glycéro*-L-*galacto*-heptonoyl]-L-lysyl}

flotegatida (^{18}F) — ciclo{L-arginilglicil-L-α-aspartil-D-fenilalanil-*N*^{6}-[2,6-anhidro-7-desoxi-7-({2-[4-(3-[^{18}F]fluoropropil)-1*H*-1,2,3-triazol-1-il]acetil}amino)-L-*glicero*-L-*galacto*-heptonoil]-L-lisil}

$C_{41}H_{60}{}^{18}FN_{13}O_{13}$



fluorfenidinum (^{18}F)

fluorfenidine (^{18}F) — 3-{2-chloro-5-[(2-[^{18}F]fluoroethyl)sulfanyl]phenyl}-1-methyl-1-[3-(methylsulfanyl)phenyl]guanidine

fluorfénidine (^{18}F) — 3-{2-chloro-5-[(2-[^{18}F]fluoroéthyl)sulfanyl]phényl}-1-méthyl-1-[3-(méthylsulfanyl)phényl]guanidine

fluorfenidina (^{18}F) — 3-{2-cloro-5-[(2-[^{18}F]fluoroetil)sulfanil]fenil}-1-metil-1-[3-(metilsulfanil)fenil]guanidine

$C_{17}H_{19}Cl^{18}FN_3S_2$



flutriciclamidum (^{18}F)

flutriciclamide (^{18}F) — (4*S*)-*N*,*N*-diethyl-9-(2-[^{18}F]fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1*H*-carbazole-4-carboxamide

flutriciclamide (^{18}F) — (4*S*)-*N*,*N*-diéthyl-9-(2-[^{18}F]fluoroéthyl)-5-méthoxy-2,3,4,9-tétrahydro-1*H*-carbazole-4-carboxamide

flutriciclamida (^{18}F)

(4*S*)-*N*,*N*-dietil-9-(2-[^{18}F]fluoroetil)-5-metoxi-2,3,4,9-tetrahidro-1*H*-carbazol-4-carboxamida

$C_{20}H_{27}{}^{18}FN_2O_2$



gandotinibum

gandotinib

3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-*N*-(5-methyl-1*H*-pyrazol-3-yl)-8-[(morpholin-4-yl)methyl]imidazo[1,2-*b*]pyridazin-6-amine

gandotinib

3-[(4-chloro-2-fluorophényl)méthyl]-2-méthyl-*N*-(5-méthyl-1*H*-pyrazol-3-yl)-8-[(morpholin-4-yl)méthyl]imidazo[1,2-*b*]pyridazin-6-amine

gandotinib

3-[(4-cloro-2-fluorofenil)metil]-2-metil-*N*-(5-metil-1*H*-pirazol-3-il)-8-[(morfolin-4-il)metil]imidazo[1,2-*b*]piridazin-6-amina

$C_{23}H_{25}ClFN_7O$



hemoglobinum crosfumarilum (bovinum) #

hemoglobin crosfumaril (bovine)

$S^{3.\beta92}$,$S^{3.\beta'92}$-bis(2-amino-2-oxoethyl)-$N^{6.\alpha99}$,$N^{6.\alpha'99}$-(but-2-enedioyl)bovine hemoglobulin ($\alpha_2\beta_2$ tetramer)

hémoglobine crosfumaril (bovine)

$S^{3.\beta92}$,$S^{3.\beta'92}$-bis(2-amino-2-oxoéthyl)-$N^{6.\alpha99}$,$N^{6.\alpha'99}$-(but-2-ènedioyl)hémoglobuline bovine ($\alpha_2\beta_2$ tétramère)

hemoglobina crosfumarilo (bovina)

$S^{3.\beta92}$,$S^{3.\beta'92}$-bis(2-amino-2-oxoetil)-$N^{6.\alpha99}$,$N^{6.\alpha'99}$-(but-2-enodioil)hemoglobulina bovina ($\alpha_2\beta_2$ tetrámero)

$C_{2826}H_{4406}N_{762}O_{802}S_{10}$

Alpha chain / Chaîne alpha / Cadena alfa

```
VLSAADKGNV KAAWGKVGGH AAEYGAEALE RMFLSFPTTK TYFPHFDLSH 50
GSAQVKGHGA KVAAALTKAV EHLDDLPGAL SELSDLHAHK LRVDPVNFKL 100
LSHSLLVTLA SHLPSDFTPA VHASLDKFLA NVSTVLTSKY R         141
```

Beta chain / Chaîne bêta / Cadena beta

```
MLTAEEKAAV TAFWGKVKVD EVGGEALGRL LVVYPWTQRF FESFGDLSTA 50
DAVMNNPKVK AHGKKVLDSF SNGMKHLDDL KGTFAALSEL HCDKLHVDPE 100
NFKLLGNVLV VVLARNFGKE FTPVLQADFQ KVVAGVANAL AHRYH      145
```

Modified residues / Résidus modifiés / Restos modificados



ilorasertibum

ilorasertib — *N*-(4-{4-amino-7-[1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]thieno[3,2-*c*]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea

ilorasertib — *N*-(4-{4-amino-7-[1-(2-hydroxyéthyl)-1*H*-pyrazol-4-yl]thiéno[3,2-*c*]pyridin-3-yl}phényl)-*N*'-(3-fluorophényl)urée

ilorasertib — *N*-(4-{4-amino-7-[1-(2-hidroxietil)-1*H*-pirazol-4-il]tieno[3,2-*c*]piridin-3-il}fenil)-*N*'-(3-fluorofenil)urea

$C_{25}H_{21}FN_6O_2S$



ipatasertibum

ipatasertib — (2*S*)-2-(4-chlorophenyl)-1-{4-[(5*R*,7*R*)-7-hydroxy-5-methyl-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-4-yl]piperazin-1-yl}-3-[(propan-2-yl)amino]propan-1-one

ipatasertib — (2*S*)-2-(4-chlorophényl)-1-{4-[(5*R*,7*R*)-7-hydroxy-5-méthyl-6,7-dihydro-5*H*-cyclopenta[*d*]pyrimidin-4-yl]pipérazin-1-yl}-3-[(propan-2-yl)amino]propan-1-one

ipatasertib — (2*S*)-2-(4-clorofenil)-1-{4-[(5*R*,7*R*)-7-hidroxi-5-metil-6,7-dihidro-5*H*-ciclopenta[*d*]pirimidin-4-il]piperazin-1-il}-3-[(propan-2-il)amino]propan-1-ona

$C_{24}H_{32}ClN_5O_2$



lexaptepidum pegolum

lexaptepid pegol — β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidine 6-{2-(*N*-[ω-methylpoly(oxyethan-1,2-diyl)]-2-{[ω-methylpoly(oxyethan-1,2-diyl)]oxy}acetamido)acetamido}hexyl hydrogen 5'-phosphate

lexaptépid pégol

β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidine 5'-hydrogenophosphate de 6-{2-(*N*-[ω-méthylpoly(oxyéthan-1,2-diyl)]-2-{[ω-méthylpoly(oxyéthan-1,2-diyl)]oxy}acétamido)acétamido}hexyle

lexaptepid pegol

β-L-guanilil-(3'→5')-β-L-citidilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-citidilil-(3'→5')-β-L-citidilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-citidilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-citidina 5'-hidrógenofosfato de 6-{2-(*N*-[ω-metilpoli(oxietan-1,2-diil)]-2-{[ω-metilpoli(oxietan-1,2-diil)]oxi}acetamido)acetamido}hexilo

$C_{441}H_{548}N_{188}O_{309}P_{44}[C_2H_4O]_{2n}$

β-L-ribo-[(3'-5')-R-pG-C-G-C-C-G-U-A-U-G-G-G-A-U-U-A-A-G-U-A-A-A-U-G-A-G-G-A-G-U-U-G-G-A-G-G-A-A-A-G-G-G-C-G-C]

R- = 

Iodelcizumabum #

Iodelcizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* PCSK9 (proprotein convertase subtilisin/kexin type 9)], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-2*05 (88.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03 (CH1 (119-216), hinge (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-448) (119-448)], (221-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV3-20*02 (87.60%) -IGKJ2*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimer (227-227":230-230")-bisdisulfide

lodelcizumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* PCSK9 (proprotéine convertase subtilisine/kexine type 9)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-2*05 (88.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) - *Homo sapiens* IGHG1*03 (CH1 (119-216), charnière (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-448) (119-448)], (221-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV3-20*02 (87.60%) -IGKJ2*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (227-227":230-230")-bisdisulfure
lodelcizumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* PCSK9 (proproteína convertasa subtilisina/kexina tipo 9)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-2*05 (88.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) - *Homo sapiens* IGHG1*03 (CH1 (119-216), bisagra (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-448) (119-448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizada (*Homo sapiens* IGKV3-20*02 (87.60%) -IGKJ2*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFS TMYMSWVRQA PGQGLEWMGR  50
IDPANEHTNY AQKFQGRVTM TRDTSISTAY MELSRLTSDD TAVYYCARSY 100
YYYNMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPEAAGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
QIVLTQSPAT LSVSPGERAT LSCRASQSVS YMHWYQQKPG QAPRLLIYGV  50
FRRATGIPDR FSGSGSGTDF TLTIGRLEPE DFAVYYCLQW SSDPPTFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    145-201    262-322   368-426
         22"-96"  145"-201"  262"-322" 368"-426"
Intra-L  23'-87'   133'-193'
         23'"-87'" 133'"-193'"
Inter-H-L  221-213'  221"-213'"
Inter-H-H  227-227"  230-230"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

```
H CH2 N84.4:
298, 298"
```

luminespibum

luminespib	5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-*N*-ethyl-4-{4-[(morpholin-4-yl)methyl]phenyl}-1,2-oxazole-3-carboxamide
luminespib	5-[2,4-dihydroxy-5-(propan-2-yl)phényl]-*N*-éthyl-4-{4-[(morpholin-4-yl)méthyl]phényl}-1,2-oxazole-3-carboxamide
luminespib	5-[2,4-dihidroxi-5-(propan-2-il)fenil]-*N*-etil-4-{4-[(morfolin-4-il)metil]fenil}-1,2-oxazol-3-carboxamida

$C_{26}H_{31}N_3O_5$



molidustatum

molidustat — 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1*H*-1,2,3-triazol-1-yl)-1,2-dihydro-3*H*-pyrazol-3-one

molidustat — 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1*H*-1,2,3-triazol-1-yl)-1,2-dihydro-3*H*-pyrazol-3-one

molidustat — 2-[6-(morfolin-4-il)pirimidin-4-il]-4-(1*H*-1,2,3-triazol-1-il)-1,2-dihidro-3*H*-pirazol-3-ona

$C_{13}H_{14}N_8O_2$



nesvacumabum #

nesvacumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* ANGPT2 (angiopoietin 2, Ang2)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-452) [*Homo sapiens* VH (IGHV3-13*01 (97.90%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -IGHG1*01 (CH1 (123-220), hinge 221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (95.80%) -IGKJ1*01) [7.3.8] (1'-107') -IGKC*01 (108'-214')]; dimer (231-231'':234-234'')-bisdisulfide

nesvacumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* ANGPT2 (angiopoïétine 2, Ang2)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-452) [*Homo sapiens* VH (IGHV3-13*01 (97.90%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -IGHG1*01 (CH1 (123-220), charnière (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V- KAPPA (IGKV3-20*01 (95.80%) -IGKJ1*01) [7.3.8] (1'-107') -IGKC*01 (108'-214')]; dimère (231-231'':234-234'')-bisdisulfure

nesvacumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* ANGPT2 (angiopoyetina 2, Ang2)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-452) [*Homo sapiens* VH (IGHV3-13*01 (97.90%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -IGHG1*01 (CH1 (123-220),bisagra (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V- KAPPA (IGKV3-20*01 (95.80%) -IGKJ1*01) [7.3.8] (1'-107') -IGKC*01 (108'-214')]; dímero (231-231'':234-234'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYDIHWVRQA TGKGLEWVSA  50
IGPAGDTYYP GSVKGRFTIS RENAKNSLYL QMNSLRAGDT AVYYCARGLI 100
TFGGLIAPFD YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS STYLAWYQQK PGQAPRLLIY  50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ HYDNSQTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-95 149-205 266-326 372-430
22"-95" 149"-205" 266"-326" 372"-430"
Intra-L 23'-89' 134'-194'
23'"-89'" 134'"-194'"
Inter-H-L 225-214' 225"-214'"
Inter-H-H 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"

nonacogum gamma #

nonacog gamma	variant_011773 (148-T>A) of human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), glycosylated (γ-glycoform)
nonacog gamma	variant_011773 (148-T>A) du facteur IX humain de coagulation (EC 3.4.21.22, facteur Christmas, facteur antihémophile B) glycosylé (glycoforme γ)
nonacog gamma	variante_011773 (148-T>A) del factor IX humano de coagulación (EC 3.4.21.22, factor Christmas, factor antihemofílico B) glicosilado (glicoforma γ)

$C_{2053}H_{3116}N_{558}O_{675}P_2S_{26}$ (peptide)

Sequence / Séquence / Secuencia

```
YNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTTE FWKQYVDGDQ  50
CESNPCLNGG SCKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK 100
NSADNKVVCS CTEGYRLAEN QKSCEPAVPF PCGRVSVSQT SKLTRAEAVF 150
PDVDYVNSTE AETILDNITQ STQSFNDFTR VVGGEDAKPG QFPWQVVLNG 200
KVDAFCGGSI VNEKWIVTAA HCVETGVKIT VVAGEHNIEE TEHTEQKRNV 250
IRIIPHHNYN AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL 300
KFGSGYVSGW GRVFHKGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC 350
AGFHEGGRDS CQGDSGGPHV TEVEGTSFLT GIISWGEECA MKGKYGIYTK 400
VSRYVNWIKE KTKLT                                        415
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
18-23 51-62 56-71 73-82 88-99 95-109
111-124 132-289 206-222 336-350 361-389

Modified residues / Résidus modifiés / Restos modificados



Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación (**N, S*, T***)
Ser-53* Ser-61* Asn-157 Thr-159* Asn-167 Thr-169* Thr-172* Thr-179*
* potential sites / sites potentiels / posiciones posibles

olaptesedum pegolum

olaptesed pegol

β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidine 6-{2-(*N*-[ω-methylpoly(oxyethan-1,2-diyl)]-2-{[ω-methylpoly(oxyethan-1,2-diyl)]oxy}acetamido)acetamido}hexyl hydrogen 5′-phosphate

olaptésed pégol

β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidine 5'-hydrogénophosphate de 6-{2-(*N*-[ω-méthylpoly(oxyéthan-1,2-diyl)]-2-{[ω-méthylpoly(oxyéthan-1,2-diyl)]oxy}acétamido)acétamido}hexyle

olaptesed pegol

β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidina 5′-hidrógenofosfato de 6-{2-(*N*-[ω-metilpoli(oxietan-1,2-diil)]-2-{[ω-metilpoli(oxietan-1,2-diil)]oxi}acetamido)acetamido}hexilo

$C_{442}H_{554}N_{169}O_{326}P_{45}[C_2H_4O]_{2n}$

β-L-*ribo*-[(3'-5')-R-pG-C-G-U-G-G-U-G-U-G-A-U-C-U-A-G-A-U-G-U-A-U-U-G-G-C-U-G-A-U-C-C-U-A-G-U-C-A-G-G-U-A-C-G-C]

R- =



ompinamerum

ompinamer — poly{[(piperazine-1,4-diyl *N*-oxide)ethylene]-*co*-[(piperazine-1,4-diyl)ethylene]}

ompinamère — poly{[(*N*-oxyde de pipérazine-1,4-diyl)éthylène]-*co*-[(pipérazine-1,4-diyl)éthylène]}

ompinámero — poli{[(*N*-óxido de piperazina-1,4-diil)etileno]-*co*-[(piperazina-1,4-diil)etileno]}

$[[C_6H_{12}N_2]_x\ [C_6H_{12}N_2O]_y]_n$



x = 8-9 , *y* = 1-2 , *n* = 8-24

ozanezumabum #

ozanezumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* RTN4 (reticulon 4, neurite outgrowth inhibitor, NOGO), isoform A], humanized monoclonal antibody;
gamma1 heavy chain (1-443) [humanized VH (*Homo sapiens* IGHV1-46*01 (86.50%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*01 (CH1 (114-211), hinge (212-226), CH2 L1.2>A (231), G1>A (233) (227-336), CH3 (337-441), CHS (442-443) (114-443)], (216-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*01 (80.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimer (222-222":225-225")-bisdisulfide

ozanezumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* RTN4 (réticulon 4, inhibiteur de la croissance des neurites, NOGO), isoforme A], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-443) [VH humanisé (*Homo sapiens* IGHV1-46*01 (86.50%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*01 (CH1 (114-211), charnière (212-226), CH2 L1.2>A (231), G1>A (233) (227-336), CH3 (337-441), CHS (442-443) (114-443)], (216-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*01 (80.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (222-222":225-225")-bisdisulfure

ozanezumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* RTN4 (reticulon 4, inhibidor del crecimiento de las neuritas, NOGO), isoforma A], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-443) [VH humanizada (*Homo sapiens* IGHV1-46*01 (86.50%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*01 (CH1 (114-211), bisagra (212-226), CH2 L1.2>A (231), G1>A (233) (227-336), CH3 (337-441), CHS (442-443) (114-443)], (216-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2-30*01 (80.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (222-222":225-225")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWMHWVRQA PGQGLEWIGN  50
INPSNGGTNY NEKFKSKATM TRDTSTSTAY MELSSLRSED TAVYYCELMQ 100
GYWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV 150
TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TQTYICNVNH 200
KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL AGAPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS 350
RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK        443
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPLS NPVTLGQPVS ISCRSSKSLL YKDGKTYLNW FLQRPGQSPQ  50
LLIYLMSTRA SGVPDRFSGG GSGTDFTLKI SRVEAEDVGV YYCQQLVEYP 100
LTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 140-196 257-317 363-421
22"-96" 140"-196" 257"-317" 363"-421"
Intra-L 23'-93' 139'-199'
23'"-93'" 139'"-199'"
Inter-H-L 216-219' 216"-219'"
Inter-H-H 222-222" 225-225"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
293, 293'

peginterferonum beta-1a #

peginterferon beta-1a

$N^{2.1}$-{(2*RS*)-2-methyl-3-[ω-methoxypoly(oxyethylene)]propyl}human interferon beta (fibroblast interferon, IFN-beta) glycosylated expressed in mammalian cells

péginterféron bêta-1a

$N^{2.1}$-{(2*RS*)-2-méthyl-3-[ω-méthoxypoly(oxyéthylène)]propyl}interféron bêta humain (interféron fibroblastoïde, IFN-bêta) glycosylé produit par les cellules de mammifères

peginterferón beta-1a

$N^{2.1}$-{(2*RS*)-2-metil-3-[ω-metoxipoli(oxietileno)]propil}interferón beta humano (interferón fibroblastoide, IFN-beta) glicosilado producido por las células de mamífero

$C_{913}H_{1417}N_{246}O_{256}PS_7$ $[C_2H_4O]_n$

Sequence / Séquence / Secuencia

```
MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF 50
QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT 100
VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI 150
LRNFYFINRL TGYLRN                                      166
```

Disulfide bridge location / Position du pont disulfure / Posicion del puente disulfuro
31-141

Modified residues / Résidus modifiés / Restos modificados



Glycosylation site (N) / Site de glycosylation (N) / Posicion de glicosilación (N)
Asn-80

pexastimogenum devacirepvecum #

pexastimogene devacirepvec	recombinant vaccinia virus vector (Wyeth strain) with its thymidine kinase gene de-activated by insertion of a GM-CSF (Granulocytes-macrophages colony stimulating factor) gene under the control of a synthetic early/late promoter and a beta-galactosidase gene under the control of the p7.5 early/late promoter
pexastimogène dévacirépvec	vecteur viral recombinant répliquant de la vaccine avec son gène de la thymidine kinase désactivé par l'insertion du gène GM-CSF(facteur de stimulation des colonies de granulocytes et de macrophages) sous le contrôle d'un promoteur synthétique précoce tardif et d'un gène de bêta-galactosidase sous le contrôle du promoteur p7.5 précoce tardif
pexastimogén devacirepvec	vector virus vaccinia recombinante replicante con el gen de la timidina kinasa desactivado por inserción del gen GM-CSF(factor de estimulación de colonias de granulocitos y macrófagos) bajo control de un promotor sintético precoz tardío y de un gen de beta-galactosidasa bajo control del promotor p7.5 precoz tardío

pidilizumabum #

pidilizumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV7-4-1*03 (83.50%) -(IGHD)-IGHJ3*01 M11>L (112)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (CH1 (118-215), hinge 216-230, CH2 (231-340), CH3 (341-445), CHS (446-447)], (220-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (75.80%) -IGKJ4*01 V9 >L (103)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimer (226-226":229-229")-bisdisulfide
pidilizumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV7-4-1*03 (83.50%) -(IGHD)-IGHJ3*01 M11>L (112)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (CH1 (118-215), charnière 216-230, CH2 (231-340), CH3 (341-445), CHS (446-447)], (220-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (75.80%) -IGKJ4*01 V9 >L (103)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (226-226":229-229")-bisdisulfure
pidilizumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV7-4-1*03 (83.50%) -(IGHD)-IGHJ3*01 M11>L (112)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 (CH1 (118-215),bisagra 216-230, CH2 (231-340), CH3 (341-445), CHS (446-447)], (220-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (75.80%) -IGKJ4*01 V9 >L (103)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGSE LKKPGASVKI SCKASGYTFT NYGMNWVRQA PGQGLQWMGW  50
INTDSGESTY AEEFKGRFVF SLDTSVNTAY LQITSLTAED TGMYFCVRVG 100
YDALDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPSS LSASVGDRVT ITCSARSSVS YMHWFQQKPG KAPKLWIYRT  50
SNLASGVPSR FSGSGSGTSY CLTINSLQPE DFATYYCQQR SSFPLTFGGG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261"-321" 367"-425"
Intra-L 23'-87' 133'-193'
23'"-87'" 133'"-193'"
Inter-H-L 220-213' 220"-213'"
Inter-H-H 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
297, 297"

pilaralisibum

pilaralisib — 2-amino-*N*-(3-{[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl}phenyl)-2-methylpropanamide

pilaralisib — 2-amino-*N*-(3-{[3-(2-chloro-5-méthoxyanilino)quinoxalin-2-yl]sulfamoyl}phényl)-2-méthylpropanamide

pilaralisib — 2-amino-*N*-(3-{[3-(2-cloro-5-metoxianilino)quinoxalin-2-il]sulfamoil}fenil)-2-metilpropanamida

$C_{25}H_{25}ClN_6O_4S$



pinatuzumabum vedotinum #

pinatuzumab vedotin — immunoglobulin G1-kappa auristatin E conjugate, anti-[*Homo sapiens* CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14)], humanized monoclonal antibody conjugated to auristatin E;
gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens* IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide (if not conjugated) with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidecaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC) linker
For the *vedotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"**.

pinatuzumab védotine

immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[*Homo sapiens* CD22 (Ig-like lectine 2 liant l'acide sialique, SIGLEC2, SIGLEC-2, molécule d'adhésion cellulaire du lymphocyte B, BL-CAM, Leu-14)], anticorps monoclonal humanisé conjugué à l'auristatine E;
chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens* IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure (si non conjugué) avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable maléimidecaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC)
Pour la partie *védotine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

pinatuzumab vedotina

inmunoglobulina G1-kappa conjugada con auristatina E, anti-[*Homo sapiens* CD22 (Ig-like lectine 2 que liga ácido siálico, SIGLEC2, SIGLEC-2, molécula d'adhesión celular del linfocito B, BL-CAM, Leu-14)], anticuerpo monoclonal humanizado conjugado con auristatina E;
cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens* IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro (si no conjugado) con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (229-229":232-232")-bisdisulfuro; conjugado, en 3 - 4 restos cistenil por término medio, con monometilauristatina E (MMAE), mediante un vínculo escindible maleimidacaproil-valil-citrulinil-*p*-aminobencilcarbamato (mc-val-cit-PABC)
Para la fracción vedotina , se pueden dirigir al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGYEFS RSWMNWVRQA PGKGLEWVGR  50
IYPGDGDTNY SGKFKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARDG 100
SSWDWYFDVW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRSSQSIV HSVGNTFLEW YQQKPGKAPK  50
LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCFQGSQFP 100
YTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L 23'-93' 139'-199'
23'"-93'" 139'"-199'"
Inter-H-L* 223-219' 223"-219'"
Inter-H-H* 229-229" 232-232"
*Two or three of the inter-chain disulfide bridges are not present, the antibody being conjugated to an average of 3 to 4 drug linkers each via a thioether bond.
* Deux ou trois des ponts disulfure inter-chaines ne sont pas présents, l'anticorps étant conjugué à une moyenne de 3 à 4 linker-principe actif chacun via une liaison thioéther.
* Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 3 a 4 conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300" but lacking carbohydrate/hydrate de carbone manquant/ falta hidrato de carbono

Other post-translational modifications
Autres modifications post-traductionnelles
Otras modificaciones post-traduccionales
Lacking H chain C-terminal lysine (CHS K2>del)

piromelatinum

piromelatine — *N*-[2-(5-methoxy-1*H*-indol-3-yl)ethyl]-4-oxo-4*H*-pyran-2-carboxamide

piromélatine — *N*-[2-(5-méthoxy-1*H*-indol-3-yl)éthyl]-4-oxo-4*H*-pyran-2-carboxamide

piromelatina — *N*-[2-(5-metoxi-1*H*-indol-3-il)etil]-4-oxo-4*H*-piran-2-carboxamida

$C_{17}H_{16}N_2O_4$



polatuzumabum vedotinum #

polatuzumab vedotin — immunoglobulin G1-kappa auristatin E conjugate, anti-[*Homo sapiens* CD79B (immunoglobulin-associated CD79 beta)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (CH1 R120>K (214) (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (220-218')-disulfide (if not conjugated) with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-218')]; dimer (226-226":229-229")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidecaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC) linker
For the *vedotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

polatuzumab védotine — immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[*Homo sapiens* CD79B (CD79 bêta associé à l'immunoglobuline)], anticorps monoclonal humanisé conjugué à l'auristatine E;
chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (CH1 R120>K (214) (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (220-218')-disulfure (si non conjugué) avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-218')]; dimère (226-226":229-229")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable maléimidecaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC)
Pour la partie *védotine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

polatuzumab vedotina	inmunoglobulina G1-kappa conjugada con auristatina E, anti-[*Homo sapiens* CD79B (CD79 beta asociado a la inmunoglobulina)], anticuerpo monoclonal humanizado conjugado con auristatina E; cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03 (CH1 R120>K (214) (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (220-218')-disulfuro (si no está conjugado) con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-218')]; dímero (226-226":229-229")-bisdisulfuro; conjugado, en 3 - 4 restos cisteinil por término medio, con monometilauristatina E (MMAE), mediante un vínculo escindible maleimidacaproil-valil-citrulinil-*p*-aminobencilcarbamato (mc-val-cit-PABC) Para la fracción *vedotina* se pueden referir al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGYTFS SYWIEWVRQA PGKGLEWIGE  50
ILPGGGDTNY NEIFKGRATF SADTSKNTAY LQMNSLRAED TAVYYCTRRV 100
PIRLDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSS LSASVGDRVT ITCKASQSVD YEGDSFLNWY QQKPGKAPKL  50
LIYAASNLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPL 100
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 144-200 261-321 367-425
22"-96" 147"-203" 261"-321" 367"-425"
Intra-L 23'-92' 138'-198'
23'"-92'" 138'"-198'"
Inter-H-L* 220-218' 220"-218'"
Inter-H-H* 226-226" 229-229"

*Two or three of the inter-chain disulfide bridges are not present, the antibody being conjugated to an average of 3 to 4 drug linkers each via a thioether bond.
* Deux ou trois des ponts disulfure inter-chaines ne sont pas présents, l'anticorps étant conjugué à une moyenne de 3 à 4 linker-principe actif chacun via une liaison thioéther.
* Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 3 a 4 conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297" but lacking carbohydrate/hydrate de carbone manquant/ falta hidrato de carbono

Other post-translational modifications
Autres modifications post-traductionnelles
Otras modificaciones post-traduccionales
Lacking H chain C-terminal lysine (CHS K2>del)

poziotinibum

poziotinib	1-(4-{[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy}piperidin-1-yl)prop-2-en-1-one
poziotinib	1-(4-{[4-(3,4-dichloro-2-fluoroanilino)-7-méthoxyquinazolin-6-yl]oxy}pipéridin-1-yl)prop-2-èn-1-one
poziotinib	1-(4-{[4-(3,4-dicloro-2-fluoroanilino)-7-metoxiquinazolin-6-il]oxi}piperidin-1-il)prop-2-en-1-ona

$C_{23}H_{21}Cl_2FN_4O_3$



pritoxaximabum #

pritoxaximab

immunoglobulin G1-kappa, anti-[shiga toxin-producing *Escherichia coli* (STEC) shiga toxin type 1 (stx1), B subunit)], chimeric monoclonal antibody;
gamma1 heavy chain (1-454) [*Mus musculus* VH (IGHV1-12*01 -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -linker (123-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV6-23*01 -IGKJ5*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (233-233'':236-236'')-bisdisulfide

pritoxaximab

immunoglobuline G1-kappa, anti-[sous-unité B de la toxine type 1 shiga (stx1) d'*Escherichia coli* produisant des shiga-toxines (STEC)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-454) [*Mus musculus* VH (IGHV1-12*01 -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -linker (123-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-23*01 -IGKJ5*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (233-233'':236-236'')-bisdisulfure

pritoxaximab

inmunoglobulina G1-kappa, anti-[subunidad B de la toxina tipo 1 shiga (stx1) de *Escherichia coli* productor de toxinas shiga (STEC)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-454) [*Mus musculus* VH (IGHV1-12*01 -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -vínculo (123-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-23*01 -IGKJ5*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (233-233'':236-236'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGAE LVRSGASVRM SCKASGYTFT SYNMHWVKQT PGQGLEWIGY  50
IYPGNGGTNY IQKFKGKAIL TADTSSSTAY MQISSLTSED SAVYFCTRSP 100
SHYSSDPYFD YWGQGTTLTV SSEFASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMSQSHKF MSTSVGDRVS ITCKASQDVG TAVAWYQQNP GQSPKFLIYW  50
ASTRHTGVPD RFTGSGSGTD FTLTITNVQS EDLADYFCQQ YSSYPLTFGA 100
GTSLELKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96    151-207    268-328    374-432
          22"-96"  151"-207"  268"-328"  374"-432"
Intra-L   23'-88'    134'-194'
          23'"-88'"  134'"-194'"
Inter-H-L   227-214'   227"-214'"
Inter-H-H   233-233"   236-236"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

```
H CH2 N84.4:
304, 304"
```

ramaterceptum #

ramatercept

fusion protein for immune applications (FPIA) comprising *Homo sapiens* ACVR2B (activin A receptor type IIB, ActR-IIB) fragment, fused with *Homo sapiens* immunoglobulin G1 Fc fragment;
Homo sapiens ACVR2B precursor fragment 20-134 (1-115) -triglycyl (116-118) -*Homo sapiens* IGHG1*03 H-CH2-CH3 fragment (hinge 8-15 (119-126), CH2 A115>V (226) (127-236), CH3 (237-341), CHS (342-343)) (119-343); dimer (122-122':125-125')-bisdisulfide

ramatercept

protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'*Homo sapiens* ACVR2B (récepteur de type IIB de l'activine A, ActR-IIB), fusionné au fragment Fc de l'*Homo sapiens* immunoglobuline G1;
Homo sapiens ACVR2B fragment 20-134 du précurseur (1-115) -triglycyl (116-118) -*Homo sapiens* IGHG1*03 fragment H-CH2-CH3 (charnière 8-15 (119-126), CH2 A115>V (226) (127-236), CH3 (237-341), CHS (342-343)) (119-343)]; dimère (122-122':125-125')-bisdisulfure

ramatercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de *Homo sapiens* ACVR2B (receptor de tipo IIB de la activina A, ActR-IIB), fusionado con el fragmento Fc de la *Homo sapiens* inmunoglobulina G1;
Homo sapiens ACVR2B fragmento 20-134 del precursor (1-115) -triglicil (116-118) -*Homo sapiens* IGHG1*03 fragmento H-CH2-CH3 (bisagra 8-15 (119-126), CH2 A115>V (226) (127-236), CH3 (237-341), CHS (342-343)) (119-343)]; dímero (122-122':125-125')-bisdisulfuro

Fused chain / Chaîne fusionnée / Cadena fusionada

```
GRGEAETREC IYYNANWELE RTNQSGLERC EGEQDKRLHC YASWRNSSGT  50
IELVKKGCWL DDFNCYDRQE CVATEENPQV YFCCCEGNFC NERFTHLPEA 100
GGPEVTYEPP PTAPTGGGTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 150
RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS 200
VLTVLHQDWL NGKEYKCKVS NKALPVPIEK TISKAKGQPR EPQVYTLPPS 250
REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 300
FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK        343
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-chain  10-40   30-58   65-84   71-83   85-90   157-217  263-321
            10'-40'  30'-58'  65'-84'  71'-83'  85'-90'  157'-217'  263'-321'
Inter-chains  122-122'  125-125'
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
23, 46, 193 (CH2 N84.4)
23', 46', 193' (CH2 N84.4)

rebastinibum

rebastinib

4-[4-({[3-*tert*-butyl-1-(quinolin-6-yl)-1*H*-pyrazol-5-yl]carbamoyl}amino)-3-fluorophenoxy]-*N*-methylpyridin-2-carboxamide

rébastinib

4-(4-{[3-*tert*-butyl-1-(quinoléin-6-yl)-1*H*-pyrazol-5-yl]carbamoyl}amino)-3-fluorophénoxy)-*N*-méthylpyridin-2-carboxamide

rebastinib

4-[4-({[3-*terc*-butil-1-(quinolin-6-il)-1*H*-pirazol-5-il]carbamoil}amino)-3-fluorofenoxi]-*N*-metilpiridin-2-carboxamida

$C_{30}H_{28}FN_7O_3$



recilisibum

recilisib — 4-[(1*E*)-2-{[(4-chlorophenyl)methyl]sulfonyl}ethenyl]benzoic acid

récilisib — acide 4-[(1*E*)-2-{[(4-chlorophényl)méthyl]sulfonyl}éthényl]benzoïque

recilisib — ácido 4-[(1*E*)-2-{[(4-clorofenil)metil]sulfonil}etenil]benzoico

$C_{16}H_{13}ClO_4S$



revexepridum

revexepride — 4-amino-5-chloro-*N*-{[(3*S*,4*S*)-3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl]methyl}-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxamide

révexépride — 4-amino-5-chloro-*N*-{[(3*S*,4*S*)-3-hydroxy-1-(3-méthoxypropyl)pipéridin-4-yl]méthyl}-2,2-diméthyl-2,3-dihydro-1-benzofurane-7-carboxamide

revexeprida — 4-amino-5-cloro-*N*-{[(3*S*,4*S*)-3-hidroxi-1-(3-metoxipropil)piperidin-4-il]metil}-2,2-dimetil-2,3-dihidro-1-benzofuran-7-carboxamida

$C_{21}H_{32}ClN_3O_4$



roxadustatum

roxadustat — *N*-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine

roxadustat — *N*-[(4-hydroxy-1-méthyl-7-phénoxyisoquinoléin-3-yl)carbonyl]glycine

roxadustat — *N*-[(4-hidroxi-1-metil-7-fenoxiisoquinolin-3-il)carbonil]glicina

$C_{19}H_{16}N_2O_5$



saroglitazarum

saroglitazar	(2*S*)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1*H*-pyrrol-1-yl}ethoxy)phenyl]propanoic acid
saroglitazar	acide (2*S*)-2-éthoxy-3-[4-(2-{2-méthyl-5-[4-(méthylsulfanyl)phényl]-1*H*-pyrrol-1-yl}éthoxy)phényl]propanoïque
saroglitazar	ácido (2*S*)-2-etoxi-3-[4-(2-{2-metil-5-[4-(metilsulfanil)fenil]-1*H*-pirrol-1-il}etoxi)fenil]propanoico

$C_{25}H_{29}NO_4S$



seribantumabum #

seribantumab	immunoglobulin G2-lambda7, anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-445) [*Homo sapiens* VH (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG2*01 (CH1 (120-217), hinge (218-229), CH2 (230-338), CH3 (339-443), CHS (444-445)) (120-445)], (133-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (94.90%) -IGLJ2*01 L9>V (108) [9.3.11] (1'-111') -IGLC7*01 (100.00%) (112'-217')]; dimer (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfide
séribantumab	immunoglobuline G2-lambda7, anti-[*Homo sapiens* ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-445) [*Homo sapiens* VH (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG2*01 (CH1 (120-217), charnière (218-229), CH2 (230-338), CH3 (339-443), CHS (444-445)) (120-445)], (133-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V- LAMBDA (IGLV2-23*02 (94.90%) -IGLJ2*01 L9>V (108) [9.3.11] (1'-111') -IGLC7*01 (100.00%) (112'-217')]; dimère (221-221'':222-222'':225-225'':228-228'')-tétrakisdisulfure

seribantumab

inmunoglobulina G2-lambda7, anti-[*Homo sapiens* ERBB3 (receptor tirosina-proteína kinasa erbB3, HER3)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma2 (1-445) [*Homo sapiens* VH (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG2*01 (CH1 (120-217), bisagra(218-229), CH2 (230-338), CH3 (339-443), CHS (444-445)) (120-445)], (133-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V- LAMBDA (IGLV2-23*02 (94.90%) -IGLJ2*01 L9>V (108) [9.3.11] (1'-111') -IGLC7*01 (100.00%) (112'-217')]; dímero (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYVMAWVRQA PGKGLEWVSS  50
ISSSGGWTLY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCTRGL 100
KMATIFDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY 200
TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPVAGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300
VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP 350
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
QSALTQPASV SGSPGQSITI SCTGTSSDVG SYNVVSWYQQ HPGKAPKLII  50
YEVSQRPSGV SNRFSGSKSG NTASLTISGL QTEDEADYYC CSYAGSSIFV 100
IFGGGTKVTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL VSDFYPGAVT 150
VAWKADGSPV KVGVETTKPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCRV 200
THEGSTVEKT VAPAECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    146-202    259-319    365-423
         22"-96"  146"-202"  259"-319"  365"-423"
Intra-L  22'-90'   139'-198'
         22'''-90'''  139'''-198'''
Inter-H-L  133-216'  133"-216'''
Inter-H-H  221-221"  222-222"  225-225"  228-228"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"

setoxaximabum #

setoxaximab

immunoglobulin G1-kappa, anti-[shiga toxin-producing *Escherichia coli* (STEC) shiga toxin type 2 (stx2), A subunit)], chimeric monoclonal antibody;
gamma1 heavy chain (1-451) [*Mus musculus* VH (IGHV1-39*01 -(IGHD)-IGHJ1*01) [8.8.12] (1-119) -linker (120-121) -*Homo sapiens* IGHG1*01 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451) (122-451)], (224-220')-disulfide with kappa light chain (1'-220') [*Mus musculus* V-KAPPA (IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dimer (230-230'':233-233'')-bisdisulfide

sétoxaximab

immunoglobuline G1-kappa, anti-[sous-unité A de la toxine type 2 shiga (stx2) d'*Escherichia coli* produisant des shiga-toxines (STEC)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-451) [*Mus musculus* VH (IGHV1-39*01 -(IGHD)-IGHJ1*01) [8.8.12] (1-119) -linker (120-121) -*Homo sapiens* IGHG1*01 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-220')-disulfure avec la chaîne légère kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; (230-230'':233-233'')-bisdisulfure

setoxaximab

inmunoglobulina G1-kappa, anti-[subunidad A de la toxina tipo 2 shiga (stx2) de *Escherichia coli* productor de toxinas shiga (STEC)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-451) [*Mus musculus* VH (IGHV1-39*01 -(IGHD)-IGHJ1*01) [8.8.12] (1-119) -vínculo(120-121) -*Homo sapiens* IGHG1*01 (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-220')-disulfuro con la cadena ligera kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; (230-230":233-233")-bisdisulfura

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQQPGPE LEKPGASVKL SCKASGYSFT DYNMNWVKQN NGESLEWIGK  50
IDPYYGGPSY NQKFKDKATL TVDKSSSTAY MQLKSLTSED SAVYYCTRGG 100
NRDWYFDVWG AGTTLTVSAE FASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLSQSPSS LVVSVGEKVT MSCKSSQSLL YSRNQKNYLA WYQQKPGQSP  50
KVLIYWASTR ESGVPDRLTG SGSGTDFTLT ISSVKAEDLA VYYCQQYYSY 100
PLTFGAGTKL ELKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    148-204    265-325    371-429
         22"-96"  148"-204"  265"-325"  371"-429"
Intra-L  23'-94'   140'-200'
         23'"-94'" 140'"-200'"
Inter-H-L  224-220'  224"-220'"
Inter-H-H  230-230"  233-233"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"

sofosbuvirum

sofosbuvir

propan-2-yl *N*-[(*S*)-{[(2*R*,3*R*,4*R*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy}phenoxyphosphoryl]-L-alaninate

sofosbuvir

N-[(*S*)-{[(2*R*,3*R*,4*R*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-4-fluoro-3-hydroxy-4-méthyloxolan-2-yl]méthoxy}phénoxyphosphoryl]-L-alaninate de propan-2-yle

sofosbuvir

N-[(*S*)-{[(2*R*,3*R*,4*R*,5*R*)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il)-4-fluoro-3-hidroxi-4-metiloxolan-2-il]metoxi}fenoxifosforil]-L-alaninato de propan-2-ilo

$C_{22}H_{29}FN_3O_9P$



tecemotidum

tecemotide — human mucin-1 (carcinoma-associated mucin, episialin, CD227)-(107-131)-peptide (sequence 40 times repeated) fusion protein with 6-*N*-hexadecanoyl-L-lysylglycine

técémotide — mucine-1 humaine (mucine associée au carcinome, épisialine, CD227)-(107-131)-peptide (fragment présent 40 fois) protéine de fusion avec la 6-*N*-hexadécanoyl-L-lysylglycine

tecemotida — mucina-1 humana (mucina asociada al carcinoma, episialina, CD227)-(107-131)-péptido (fragmento presente 40 veces) proteína de fusión con la 6-*N*-hexadecanoil-L-lisilglicina

$C_{124}H_{203}N_{33}O_{38}$

Sequence / Séquence / Secuencia

```
STAPPAHGVT SAPDTRPAPG STAPPKG     27
```

Modified residue / Résidu modifié / Resto modificado



telmapitantum

telmapitant — (5*R*,8*S*)-8-({(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione

telmapitant — (5*R*,8*S*)-8-({(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy}méthyl)-8-phényl-1,3,7-triazaspiro[4.5]décane-2,4-dione

telmapitant — (5*R*,8*S*)-8-({(1*R*)-1-[3,5-bis(trifluorometil)fenil]etoxi}metil)-8-fenil-1,3,7-triazaspiro[4.5]decano-2,4-diona

$C_{24}H_{23}F_6N_3O_3$



tildrakizumabum #

tildrakizumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* IL23A (interleukin 23 alpha subunit (p19), IL-23A)], humanized monoclonal antibody; gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV1-18*01 (81.60%) -(IGHD)-IGHJ4*01)) [8.8.9] (1-116) -*Homo sapiens* IGHG1*01 (CH1 (117-214, hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (225-225":228-228")-bisdisulfide

tildrakizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL23A (sous-unité alpha (p19) de l'interleukine 23, IL-23A)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens* IGHV1-18*01 (81.60%) -(IGHD)-IGHJ4*01)) [8.8.9] (1-116) -*Homo sapiens* IGHG1*01 (CH1 (117-214, charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (225-225":228-228")-bisdisulfure

tildrakizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL23A (subunidad alfa (p19) de la interleukina 23, IL-23A)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens* IGHV1-18*01 (81.60%) -(IGHD)-IGHJ4*01)) [8.8.9] (1-116) -*Homo sapiens* IGHG1*01 (CH1 (117-214, bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYIFI TYWMTWVRQA PGQGLEWMGQ  50
IFPASGSADY NEKFEGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARGG 100
GGFAYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRTSENIY SYLAWYQQKP GKAPKLLIYN  50
AKTLAEGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQH HYGIPFTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96    143-199    260-320    366-424
          22"-96"  143"-199"  260"-320"  366"-424"
Intra-L   23'-88'    134'-194'
          23'"-88"'  134'"-194'"
Inter-H-L 219-214'   219"-214'"
Inter-H-H 225-225"   228-228"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"

tomicoratum

tomicorat

4-{5-[(5-fluoro-2-methylphenoxy)methyl]-2,2,4-trimethyl-1,2-dihydroquinolin-6-yl}-3-methoxyphenyl furan-2-carboxylate

tomicorat

furane-2-carboxylate de 4-{5-[(5-fluoro-2-méthylphénoxy)méthyl]-2,2,4-triméthyl-1,2-dihydroquinoléin-6-yl}-3-méthoxyphényle

tomicorat	furan-2-carboxilato de 4-{5-[(5-fluoro-2-metilfenoxi)metil]-2,2,4-trimetil-1,2-dihidroquinolin-6-il}-3-metoxifenilo $C_{32}H_{30}FNO_5$ 

turoctocogum alfa pegolum #

turoctocog alfa pegol	human coagulation factor VIII-(1-750)-(1638-1648)-peptide compound with human coagulation factor VIIIa light chain, glycosylated and pegylated; *O*$^{3.750}$-[α-methylpoly(oxyethylene) 5-(acetylamino)-2,5-dideoxy-D-*glycero*-β-D-*galacto*-non-2-ulopyranosylonate-(2→4)-α-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl]-des-(751-1637)-human coagulation factor VIII-(1-1648)-peptide containing 92 kDa factor VIIIa heavy chain compound with human coagulation factor VIIIa light chain glycosylated (glycoform alfa produced in CHO cells)
turoctocog alfa pégol	facteur VIII de coagulation humain-(1-750)-(1638-1648)-peptide associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés et pégylés *O*$^{3.750}$-[5-(acétylamino)-2,5-didéoxy-D-*glycéro*-β-D-*galacto*-non-2-ulopyranosylonate de α-méthylpoly(oxyéthylène)-(2→4)-α-D-galactopyranosyl-(1→4)-2-(acétylamino)-2-déoxy-α-D-galactopyranosyl]-dès-(751-1637)-facteur VIII de coagulation humain-(1-1648)-peptide contenant la chaîne lourde de 92 kDa du factor VIIIa associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés (glycoforme alfa produit par des cellules CHO)
turoctocog alfa pegol	factor VIII de coagulación humano-(1-750)-(1638-1648)-péptido asociado a la cadena ligera del factor VIIIa de coagulación humano glicosilados y pegilados; *O*$^{3.750}$-[5-(acetilamino)-2,5-didesoxi-D-*glicero*-β-d-*galacto*-non-2-ulopiranosilonato de α-metilpoli(oxietileno)-(2→4)-α-D-galactopiranosil-(1→4)-2-(acetlamino)-2-desoxi-α-D-galactopiranosil]-des-(751-1637)-factor VIII de coagulación humano-(1-1648)-péptido que contiene la cadena pesada de 92 kDa del factor VIIIa asociado a la cadena ligera del factor VIIIa de coagulación humano glicosilados (glicoforma alfa producido por células CHO)

Heavy chain / Chaîne lourde / Cadena pesada

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNSRHPS 750
QNPPVLKRHQ R                                          761
```

Light chain / Chaîne légère / Cadena ligera

```
                                                      EI 1650
TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTRHYFI 1700
AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD GSFTQPLYRG 1750
ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800
EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850
LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900
APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950
ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFETVEMLP SKAGIWRVEC 2000
LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYGQWAPKL 2050
ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100
FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150
LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200
ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250
LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TPVVNSLDPP 2300
LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY                    2332
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Sulfated residues (Y) / Résidus sulfatés (Y) / Restos sulfatados (Y)
Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-1664 Tyr-1680

Modified residue / Résidu modifié / Resto modificado



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-41 Asn-239 Asn-1810 Asn-2118

ulodesinum

ulodesine	7-{[(3*R*,4*R*)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl}-1,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one
ulodésine	7-{[(3*R*,4*R*)-3-hydroxy-4-(hydroxyméthyl)pyrrolidin-1-yl]méthyl}-1,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one
ulodesina	7-{[(3*R*,4*R*)-3-hidroxi-4-(hidroximetil)pirrolidin-1-il]metil}-1,5-dihidro-4*H*-pirrolo[3,2-*d*]pirimidin-4-ona

$C_{12}H_{16}N_4O_3$



vibegronum

vibegron (6*S*)-*N*-[4-({(2*S*,5*R*)-5-[(*R*)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-*a*]pyrimidine-6-carboxamide

vibégron (6*S*)-*N*-[4-({(2*S*,5*R*)-5-[(*R*)-hydroxyphénylméthyl]pyrrolidin-2-yl}méthyl)phényl]-4-oxo-4,6,7,8-tétrahydropyrrolo[1,2-*a*]pyrimidine-6-carboxamide

vibegrón (6*S*)-*N*-[4-({(2*S*,5*R*)-5-[(*R*)-hidroxi(fenil)metil]pirrolidin-2-il}metil)fenil]-4-oxo-4,6,7,8-tetrahidropirrolo[1,2-*a*]pirimidina-6-carboxamida

$C_{26}H_{28}N_4O_3$



voxtalisibum

voxtalisib 2-amino-8-ethyl-4-methyl-6-(1*H*-pyrazol-3-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

voxtalisib 2-amino-8-éthyl-4-méthyl-6-(1*H*-pyrazol-3-yl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

voxtalisib 2-amino-8-etil-4-metil-6-(1*H*-pirazol-3-il)pirido[2,3-*d*]pirimidin-7(8*H*)-ona

$C_{13}H_{14}N_6O$



zamicastatum

zamicastat 5-(2-(benzylamino)ethyl)-1-[(3*R*)-6,8-difluoro-3,4-dihydro-2*H*-1-benzopyran-3-yl)-1,3-dihydro-2*H*-imadazole-2-thione

zamicastat 5-[2-(benzylamino)éthyl]-1-[(3*R*)-6,8-difluoro-3,4-dihydro-2*H*-1-benzopyran-3-yl]-1,3-dihydro-2*H*-imidazole-2-thione

zamicastat 5-(2-(bencilamino)etil)-1-[(3*R*)-6,8-difluoro-3,4-dihidro-2*H*-1-benzopiran-3-il)-1,3-dihidro-2*H*-imidazol-2-tiona

$C_{21}H_{21}F_2N_3OS$



Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

* http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 36
(Información Farmacéutica OMS, Vol. 10, No. 3, 1996)

p. 147	*suprimáse*	*insertese*
	fasidotril	fasidotrilo

Recommended International Nonproprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 58
(WHO Drug Information, Vol. 21, No. 3, 2007)

p. 255 **methylnaltrexonii bromidum**

methylnaltrexone bromide — *replace the chemical name by the following one*

(17*RS*)-17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-17-methyl-6-oxo-14β-morphinanium bromide

Recommended International Nonproprietary Names (Rec. INN): List 62
Dénominations communes internationales recommendées (DCI Rec.): Liste 62
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62
(WHO Drug Information, Vol. 23, No. 3, 2009)

p. 248 **fidaxomicinum**

fidaxomicin — *replace the chemical name by the following one*

fidaxomicina — *sustitúyase el nombre químico por el siguiente*

(3*E*,5*E*,8*S*,9*E*,11*S*,12*R*,13*E*,15*E*,18*S*)-3-{[(6-deoxy-4-*O*-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-*O*-methyl-β-D-mannopyranosyl)oxy]methyl}-12-{[6-deoxy-5-*C*-methyl-4-*O*-(2-methylpropanoyl)-β-D-*lyxo*-hexopyranosyl]oxy}-11-ethyl-8-hydroxy-18-[(1*R*)-1-hydroxyethyl]-9,13,15-trimethyloxacyclooctadeca-3,5,9,13,15-pentaen-2-one

(3*E*,5*E*,8*S*,9*E*,11*S*,12*R*,13*E*,15*E*,18*S*)-3-{[(6-desoxi-4-*O*-(3,5-dicloro-2-etil-4,6-dihidroxibenzoil)-2-*O*-metil-β-D-manopiranosil)oxi]metil}-12-{[6-desoxi-5-*C*-metil-4-*O*-(2-metilpropanoil)-β-D-*lixo*-hexopiranosil]oxi}-11-etil-8-hidroxi-18-[(1*R*)-1-hidroxietil]-9,13,15-trimetiloxaciclooctadeca-3,5,9,13,15-pentaen-2-ona

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.